4D Molecular Therapeutics (4DMT) announced that management will present at three major investor conferences in March 2026: TD Cowen Health Care Conference (March 3), Leerink Global Healthcare Conference (March 10), and Barclays Global Healthcare Conference (March 12). The company is advancing late-stage biotech therapeutics including 4D-150 for retinal vascular diseases currently in Phase 3 development and 4D-710 for cystic fibrosis.

4D Molecular Therapeutics announced the appointment of Kristian Humer as Chief Financial Officer, bringing over two decades of finance and biotechnology experience to support the company's late-stage clinical development and commercial planning.

4D Molecular Therapeutics partnered with Otsuka Pharmaceutical to develop and commercialize 4D-150, a potential transformative therapy for retinal vascular diseases in the Asia-Pacific region, receiving $85 million upfront and potential milestone payments up to $336 million.

GenVivo appointed Dr. Noriyuki Kasahara as Chief Scientific Officer to advance its genetic therapy platform for cancer treatment, leveraging his extensive experience in gene therapy and vector technology research.

4D Molecular Therapeutics reported Q2 2025 financial results with $15 million revenue, exceeding estimates, driven by collaboration income. The company advanced its gene therapy programs for retinal and respiratory diseases, with promising clinical trial progress and a workforce reduction to manage expenses.

4DMT reported Q2 2025 financial results, highlighting accelerated Phase 3 clinical trials for 4D-150 in wet AMD and DME, positive 60-week trial results, and a workforce reduction to drive late-stage execution with $417 million cash runway into 2028.

4D Molecular Therapeutics will present interim results from two clinical trials evaluating 4D-150, a potential treatment for diabetic macular edema and neovascular age-related macular degeneration, at the ASRS Annual Scientific Meeting in July 2025.

The global gene therapy in ophthalmology market is experiencing robust growth, driven by the increasing prevalence of genetic eye diseases, technological advancements, and regulatory support. However, the high cost of treatments and manufacturing challenges remain key concerns.

The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency.

The cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders.

4D Molecular Therapeutics, a clinical-stage biotechnology company, announced that it will participate in fireside chats at upcoming investor conferences in March. The company's management team will also be available for one-on-one meetings.

4DMT announced positive interim data from the Phase 2b cohort of its PRISM study evaluating 4D-150 in wet AMD. The data showed significant reduction in injection burden and durable aflibercept expression, supporting the potential of 4D-150 as a backbone therapy for vascular retinal diseases.